首页> Cancer research> Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in <i>KRAS</i>-Mutant Pancreatic and Colorectal Cancer.

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in <i>KRAS</i>-Mutant Pancreatic and Colorectal Cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Jörn,Weisner

第一单位： Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany.;Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Dortmund, Germany.

作者： Jörn,Weisner ^[1] ; Ina,Landel ^[1] ; Christoph,Reintjes ^[2] ; Niklas,Uhlenbrock ^[1] ; Marija,Trajkovic-Arsic ^[3] ; Niklas,Dienstbier ^[3] ; Julia,Hardick ^[1] ; Swetlana,Ladigan ^[2] ; Marius,Lindemann ^[1] ; Steven,Smith ^[1] ; Lena,Quambusch ^[1] ; Rebekka,Scheinpflug ^[1] ; Laura,Depta ^[1] ; Rajesh,Gontla ^[1] ; Anke,Unger ^[4] ; Heiko,Müller ^[4] ; Matthias,Baumann ^[4] ; Carsten,Schultz-Fademrecht ^[4] ; Georgia,Günther ^[5] ; Abdelouahid,Maghnouj ^[2] ; Matthias P,Müller ^[1] ; Michael,Pohl ^[6] ; Christian,Teschendorf ^[7] ; Heiner,Wolters ^[8] ; Richard,Viebahn ^[9] ; Andrea,Tannapfel ^[10] ; Waldemar,Uhl ^[11] ; Jan G,Hengstler ^[5] ; Stephan A,Hahn ^[12] ; Jens T,Siveke ^[13] ; Daniel,Rauh ^[14]

作者单位： Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany.;Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Dortmund, Germany. ^[1] Department of Molecular Gastrointestinal Oncology, Ruhr-University Bochum, Bochum, Germany. ^[2] German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), partner site Essen, West German Cancer Center, University Hospital Essen, Essen, Germany. ^[3] Lead Discovery Center GmbH, Dortmund, Germany. ^[4] Leibniz Research Centre for Working Environment and Human Factors (IfADo), TU Dortmund University, Dortmund, Germany. ^[5] Department of Internal Medicine, Ruhr-University Bochum, Knappschaftskrankenhaus, Bochum, Germany. ^[6] Department of Internal Medicine, St. Josefs-Hospital, Dortmund, Germany. ^[7] Department of Visceral and General Surgery, St. Josefs-Hospital, Dortmund, Germany. ^[8] Department of Surgery, Ruhr-University Bochum, Knappschaftskrankenhaus, Bochum, Germany. ^[9] Institute of Pathology, Ruhr-University of Bochum, Bochum, Germany. ^[10] Department of Visceral and General Surgery, St. Josef Hospital, Ruhr-University Bochum, Germany. ^[11] Department of Molecular Gastrointestinal Oncology, Ruhr-University Bochum, Bochum, Germany. daniel.rauh@tu-dortmund.de stephan.hahn@rub.de jens.siveke@uk-essen.de. ^[12] German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. daniel.rauh@tu-dortmund.de stephan.hahn@rub.de jens.siveke@uk-essen.de.;Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), partner site Essen, West German Cancer Center, University Hospital Essen, Essen, Germany. ^[13] Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany. daniel.rauh@tu-dortmund.de stephan.hahn@rub.de jens.siveke@uk-essen.de.;Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Dortmund, Germany. ^[14]